Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Visualization of Host Cell Kinase Activation by Viral Proteins Using GFP Fluorescence Complementation and Immunofluorescence Microscopy. | Bio Protoc | 2021 | 34327265 | PubTator, text mining | PubMed |
| Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. | Oncogenesis | 2021 | 34315851 | PubTator, text mining | PubMed |
| Bruton's Tyrosine Kinase and Its Isoforms in Cancer. | Front Cell Dev Biol | 2021 | 34307353 | PubTator, text mining | PubMed |
| Deep-learning framework and computer assisted fatty infiltration analysis for the supraspinatus muscle in MRI. | Sci Rep | 2021 | 34301978 | PubTator, text mining | PubMed |
| Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. | Int J Mol Sci | 2021 | 34299259 | PubTator, text mining | PubMed |
| Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic. | Oncol Lett | 2021 | 34295383 | PubTator, text mining | PubMed |
| Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation. | Commun Biol | 2021 | 34294876 | PubTator, text mining | PubMed |
| Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. | PLoS One | 2021 | 34292953 | PubTator, text mining | PubMed |
| Bbc3 Loss Enhances Survival and Protein Clearance in Neurons Exposed to the Organophosphate Pesticide Chlorpyrifos. | Toxicol Sci | 2021 | 34289071 | PubTator, text mining | PubMed |
| Possible Therapeutic Strategy Involving the Purine Synthesis Pathway Regulated by ITK in Tongue Squamous Cell Carcinoma. | Cancers (Basel) | 2021 | 34283052 | PubTator, text mining | PubMed |
| Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma. | Aging (Albany NY) | 2021 | 34282055 | PubTator, text mining | PubMed |
| A Transcriptome-Wide Isoform Landscape of Melanocytic Nevi and Primary Melanomas Identifies Gene Isoforms Associated with Malignancy. | Int J Mol Sci | 2021 | 34281234 | PubTator, text mining | PubMed |
| Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. | Front Oncol | 2021 | 34277452 | PubTator, text mining | PubMed |
| BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. | Front Immunol | 2021 | 34276674 | PubTator, text mining | PubMed |
| Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. | Expert Opin Drug Metab Toxicol | 2021 | 34275396 | PubTator, text mining | PubMed |
| Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease. | Cell Transplant | 2021 | 34269100 | PubTator, text mining | PubMed |
| [Epstein-Barr virus-associated smooth muscle tumor in a girl]. | Zhongguo Dang Dai Er Ke Za Zhi | 2021 | 34266534 | PubTator, text mining | PubMed |
| SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation. | Cancer Biol Med | 2021 | 34264564 | PubTator, text mining | PubMed |
| A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. | Clin Cancer Res | 2021 | 34253577 | PubTator, text mining | PubMed |
| Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. | Front Cell Dev Biol | 2021 | 34249912 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=45